Barriers to Implement Generic Medicine Prescribing and Dispensing Policies in Pakistan: Current Challenges and Future Implication
Main Article Content
Keywords
Generic medicine, generic prescribing, generic dispensing, generic medicine policy, WHO core prescribing indicator, Pakistan
Abstract
Background: Prescriptions comprising of generic names have made place as the norm in many countries owing to established drug regulatory regimes. Nevertheless, generics have greatly reduced worldwide pharmaceutical and healthcare spending. Objective: The current review comprehensively explores research studies focused on generic medicine in Pakistan, utilizing a variety of research methodologies. The prime objective of this review is to assess the barriers toward the implementation of generic medicine prescribing and dispensing policies in Pakistan in order to reduce the prescription cost. Methodology: The articles were filtered using databases: Google Scholar and PubMed. The research questions were developed and focused exclusively on all literature available regarding generic medicine in Pakistan. Results: Google Scholar and Pub-Med were searched for the period 2000-2023. 45 studies were included as per our criteria. The selected papers were grouped into different themes. Seven (7) papers were included regarding knowledge, attitude, perception & practice of healthcare givers regarding generic medicine in Pakistan. Seven (7) studies were related to Availability, Affordability, Pricing of Generic Medicine in Pakistan while 31 studies were included regarding percentage of generic prescribing as per WHO Core indicators. Both quantitative and qualitative research studies were eligible for inclusion. the selected papers were grouped into different themes. Conclusion: With the help of the evidence available through screening, it has been revealed that situation of generic medicine is quite alarming in Pakistan. Bioequivalence regulations as well as proper generic policy are need of the day. Educational interventions and uncompromising compliance to the drug policies of WHO may play a part in generic medication prescribing. Implementation of pricing policies is compulsory to promote rational use of drugs and to enhance availability. Presence of qualified pharmacists and electronic health system at every level of healthcare setups is need of an hour.
References
1. Nations, U. About the Sustainable Development Goals 2019 [cited 2023 23 July]; Available from: https://www.un.org/
sustainabledevelopment/sustainable-development-goals/.
2. Organization, W.H. Access to medicines: making market forces serve the poor. 2017 [cited 2023 August 21 ];
Available from: https://cdn.who.int/media/docs/default-source/essential-medicines/fair-price/chapter-medicines.
pdf?sfvrsn=adcffc8f_4&download=true#:~:text=The%20world%20is%20neither.,in%20modern%20science%20and%20
medicine.&text=When%20prices%20are%20so%20low,profits%2C%20companies%20leave%20the%20market.
3. Protection, N.f.C. Prices, availability and affordability of medicines in Pakistan. [cited 2023 June 30]; Available from: https://
haiweb.org/wp-content/uploads/2015/07/Pakistan-Report-Pricing-Surveys.pdf.
4. Harrison, M.A., et al., Access to cardiovascular medicines in low-and middle-income countries: a mini review. Global Health
Research and Policy, 2023. 8(1): p. 17.
5. Godman, B., et al., Generic drugs–essential for the sustainability of healthcare systems with numerous strategies to enhance
their use. Pharmaceutical Sciences And Biomedical Analysis Journal, 2021. 4(1): p. 126.
6. Godman, B., et al., Evidence-based public policy making for medicines across countries: findings and implications for the
future. Journal of comparative effectiveness research, 2021. 10(12): p. 1019-1052. 7. Cameron, A., et al., Switching from originator brand medicines to generic equivalents in selected developing countries: how
much could be saved? Value in health, 2012. 15(5): p. 664-673.
8. Woerkom, M.v., et al., Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The
Netherlands: influence and future implications. Journal of comparative effectiveness research, 2012. 1(6): p. 527-538.
9. Godman, B., et al., Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization:
changes seen and global implications. Expert review of pharmacoeconomics & outcomes research, 2010. 10(6): p. 707-722.
10. Leporowski, A., et al., Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national
health service: influence and implications. Expert review of pharmacoeconomics & outcomes research, 2018. 18(6): p. 655-
666.
11. Zanichelli, V., et al., The WHO AWaRe (Access, Watch, Reserve) antibiotic book and prevention of antimicrobial resistance.
Bulletin of the World Health Organization, 2023. 101(4): p. 290.
12. Sharland, M., et al., Encouraging AWaRe-ness and discouraging inappropriate antibiotic use—the new 2019 Essential Medicines
List becomes a global antibiotic stewardship tool. The Lancet Infectious Diseases, 2019. 19(12): p. 1278-1280.
13. McCabe, H., et al., Prescribing trends of inhaler treatments for asthma and chronic obstructive pulmonary disease within
a resource-constrained environment in the Scottish national health service: findings and implications. Expert review of
respiratory medicine, 2019. 13(7): p. 679-689.
14. Abdulsalim, S., et al., Structured pharmacist-led intervention programme to improve medication adherence in COPD patients:
a randomized controlled study. Research in Social and Administrative Pharmacy, 2018. 14(10): p. 909-914.
15. Dylst, P., et al., Generic medicines: solutions for a sustainable drug market? Applied health economics and health policy, 2013.
11: p. 437-443.
16. Organization, W.H. Glossary of Globalization, Trade and Health Terms. 2012 [cited 2023 July 14]; Available from: www.who.
int/trade/glossary/ story034/en/index.html.
17. Suleman, F., et al., New business models for research and development with affordability requirements are needed to achieve
fair pricing of medicines. bmj, 2020. 368.
18. Godman, B., et al., Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of
healthcare systems and the implications. Expert review of pharmacoeconomics & outcomes research, 2021. 21(4): p. 527-540.
19. Hollis, A., Orphan drug pricing and costs: a case study of Kalydeco and Orkambi. Healthcare policy, 2019. 15(1): p. 70.
20. Workman, P., et al., How much longer will we put up with $100,000 cancer drugs? Cell, 2017. 168(4): p. 579-583.
21. Manzoli, L., et al., Generic versus brand-name drugs used in cardiovascular diseases. European journal of epidemiology, 2016.
31: p. 351-368.
22. Kesselheim, A.S., et al., Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic
review and meta-analysis. Jama, 2008. 300(21): p. 2514-2526.
23. Corrao, G., et al., Are generic and brand-name statins clinically equivalent? Evidence from a real data-base. European journal
of internal medicine, 2014. 25(8): p. 745-750.
24. Lessing, C., T. Ashton, and P. Davis, The impact on health outcomes and healthcare utilisation of switching to generic medicines
consequent to reference pricing: the case of lamotrigine in New Zealand. Applied health economics and health policy, 2014.
12: p. 537-546.
25. Jamshed, S.Q., M.A.A. Hassali, and M.I.M.J.J.T.J.o.t.P.M.A. Ibrahim, Knowledge attitude and perception of dispensing doctors
regarding generic medicines in Karachi, Pakistan: a qualitative study. 2011. 61(1): p. 80-83.
26. Das, N., et al., Prescribing practices of consultants at Karachi, Pakistan. 2001. 51(2): p. 74-77.
27. Aijaz, T. Generic Drugs: A Better Alternative for Low Income Countries. 2015 [cited 2023 July 28]; Available from: http://blogs.
jpmsonline.com/2015/09/19/generic-drugs-a-better-alternative-for-low-income-countries/.
28. MacBride-Stewart, S., et al., Initiatives and reforms across Scotland in recent years to improve prescribing; findings and global
implications of drug prescriptions. International Journal of Clinical and Experimental Medicine, 2021. 14(12): p. 2563-2586.
29. Garuoliene, K., et al., European countries with small populations can obtain low prices for drugs: Lithuania as a case history.
Expert review of pharmacoeconomics & outcomes research, 2011. 11(3): p. 343-349.
30. Markovic-Pekovic, V., et al., Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future
directions. Expert review of pharmacoeconomics & outcomes research, 2012. 12(5): p. 661-671.
31. Garuolienė, K., et al., Differences in utilization rates between commercial and administrative databases: implications for future
health-economic and cross-national studies. Expert review of pharmacoeconomics & outcomes research, 2016. 16(2): p. 149-
152.
32. Bayram, D., et al., Generic drug prescribing in primary care: A nationwide analysis. International Journal of Clinical Practice,
2021. 75(8): p. e14284.
33. Wong, J.Q., et al., The prevalence of Philippine prescribing, dispensing, and use behavior in relation to generic drugs and their
risk factors. 2014, PIDS Discussion Paper Series.
34. Lavtepatil, S. and S. Ghosh, Improving access to medicines by popularising generics: a study of ‘India’s People’s Medicine’scheme
in two districts of Maharashtra. BMC Health Services Research, 2022. 22(1): p. 643.
35. Pharmacopeia, U.S. Timeline: Generic medicines in the US. 2018 [cited 2023 July 31]; Available from: https://www.usp.org/our-impact/generics/timeline-of-generics-in-us.
36. Zaheer-Ud-Din Babar, S.Q.J., Ashar Muhammad Malik, Hans Löfgren, The New Political Economy of Pharmaceuticals. The
Pharmaceutical Industry, Intellectual Property Rights and Access to Medicines in Pakistan. 2013: Springer.
37. Merchant, H.A., et al., A leap towards enforcing medicines prescribing by generic names in low-and middle-income countries
(LMICs): pitfalls, limitations, and recommendations for local drug regulatory agencies. 2022. 15(1): p. 1-7.
38. Babar, A., et al., Assessment of active pharmaceutical ingredients in drug registration procedures in Pakistan: implications for
the future. Generics and Biosimilars Initiative Journal, 2016. 5(4): p. 156-163.
39. Arnet, I., et al., Pharmaceutical quality of eight generics of ceftriaxone preparation for injection in Eastern Asia. Journal of
chemotherapy, 2015. 27(6): p. 337-342.
40. Redfern, J., et al., Equivalence in active pharmaceutical ingredient of generic antihypertensive medicines available in Nigeria
(EQUIMEDS): a case for further surveillance. Global heart, 2019. 14(3): p. 327-333.
41. Fadare, J.O., et al., The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians. Expert
review of pharmacoeconomics & outcomes research, 2016. 16(5): p. 639-650.
42. Bank, T.W. Data for Lower middle income, Pakistan 2023 [cited 2023 Aug 2]; Available from: https://data.worldbank.
org/?locations=XN-PK.
43. Saeed, A., et al., Access to essential cardiovascular medicines in Pakistan: a national survey on the availability, price, and
affordability, using WHO/HAI methodology. 2021. 11: p. 595008.
44. Saeed, A., et al., Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A crosssectional
survey using WHO/HAI methodology. 2019. 14(4): p. e0216122.
45. Saleem, F., et al., Uncontrollable medicine prices in Pakistan. 2016. 388(10060): p. 2602.
46. Jamshed, S.Q., et al., Perception and attitude of general practitioners regarding generic medicines in Karachi, Pakistan: a
questionnaire based study. 2012. 5(1): p. 22.
47. Godman, B., et al., Evidence-based public policy making for medicines across countries: findings and implications for the
future. J Comp Eff Res, 2021. 10(12): p. 1019-1052.
48. Saeed, A., et al., Impact of National Drug Pricing Policy 2018 on access to medicines in Lahore division, Pakistan: a pre-post
survey study using WHO/HAI methodology. BMJ open, 2020. 10(10): p. e034720.
49. Zaidi, S., et al., Access to essential medicines in Pakistan: policy and health systems research concerns. PloS one, 2013. 8(5):
p. e63515.
50. McGinn, D., et al., Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and
implications. Expert review of pharmacoeconomics & outcomes research, 2010. 10(1): p. 73-85.
51. Zaidi, S., et al., Access to essential medicines in Pakistan: policy and health systems research concerns. 2013. 8(5): p. e63515.
52. INITIATIVE, G.A.B. Generics in Pakistan. 2012 [cited 2023 Aug 2]; Available from: https://www.gabionline.net/generics/
research/Generics-in-Pakistan.
53. Pakistan, D.R.A.o. Amendments in the Drug Pricing Policy-2018. [cited 2023 December 13]; Available from: https://www.dra.
gov.pk/about_us/legislation/sros/sro-678i-2023-amendments-in-the-drug-pricing-policy-2018/.
54. Merchant, H.A., Z.-U.-D. Babar, and I.M. Hussain, A leap towards enforcing medicines prescribing by generic names in low-and
middle-income countries (LMICs): pitfalls, limitations, and recommendations for local drug regulatory agencies. Journal of
Pharmaceutical Policy and Practice, 2022. 15(1): p. 1-7.
55. Pakistan, D.R.A.o. Applications for Registration of Multiple Strength and Volume Drugs (Pharmaceutical) on Form-5F. [cited
2023 December 16]; Available from: https://www.dra.gov.pk/news_updates/regulatory_updates/drugs/notificationregarding-
data-requirements-of-form-5-f-for-pharmaceutical-drug-products-having-multiple-strengths-fill-volumes/.
56. Hasan, S.K.J.J.o.t.D.U.o.H.S., Prospects of drug bioequivalence studies in Pakistan. 2012. 6(2): p. 39-41.
57. News, T. Generic Medicines Flooding Market Sans Tests, Research. 2012 [cited 2023 Aug 6]; Available from: https://www.
thenews.com.pk/archive/print/343372-generic-medicines-flooding-market-sans--tests-research .
58. Khan, N., et al., Perceptions and attitudes of medical sales representatives (MSRs) and prescribers regarding pharmaceutical
sales promotion and prescribing practices in Pakistan. 2016. 8(3): p. 244-250.
59. Alam, M., et al., Tackling antimicrobial resistance in primary care facilities across Pakistan: Current challenges and implications
for the future. Journal of Infection and Public Health, 2023.
60. Abdullah, S., Z. Saleem, and B. Godman, Coping with increasing medicine costs through greater adoption of generic prescribing
and dispensing in Pakistan as an exemplar country. 2024, Taylor & Francis. p. 167-170.
61. Haddaway, N.R., et al., PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with
interactivity for optimised digital transparency and Open Synthesis. Campbell Systematic Reviews, 2022. 18(2): p. e1230.
62. Jamshed, S., et al., Knowledge, perception and attitude of community pharmacists towards generic medicines in Karachi,
Pakistan: a qualitative insight. Tropical Journal of Pharmaceutical Research, 2010. 9(4).
63. Jamshed, S.Q., et al., Understanding and perceptions of final-year Doctor of Pharmacy students about generic medicines in
Karachi, Pakistan: a quantitative insight. 2015: p. 359-366.
64. Masood, I., A. Saleem, and S.Q.J.J.o.P.H.S.R. Jamshed, Why do physicians prefer brand medicines over generic medicines in
Pakistan? A quantitative approach. 2016. 7(4): p. 247-251. 65. Asif, U., et al., Exploring the knowledge and attitude of medical and pharmacy students about generic medicine in Lahore,
Pakistan. Journal of Generic Medicines, 2018. 14(1): p. 22-28.
66. Tauqeer Hussain MALLHI, Y.H.K., Shahid SHAH, Ghulam ABBAS, Usman Rashid CHAND, Knowledge, Attitude and Practice of
Community Pharmacists Regarding Generic Medicines: A National Cross-Sectional Survey. Latin American Journal of Pharmacy,
2022. 41(10): p. 1962-70.
67. Sarwar, M.R., S. Iftikhar, and A. Saqib, Availability of anticancer medicines in public and private sectors, and their affordability
by low, middle and high-income class patients in Pakistan. BMC cancer, 2018. 18(1): p. 1-11.
68. Saqib, A., S. Iftikhar, and M.R. Sarwar, Availability and affordability of biologic versus non-biologic anticancer medicines: a
cross-sectional study in Punjab, Pakistan. BMJ open, 2018. 8(6): p. e019015.
69. Saleem, Z., et al., WHO key access antibiotics prices, availability and affordability in private sector pharmacies in Pakistan. Cost
Effectiveness and Resource Allocation, 2021. 19(1): p. 1-10.
70. Bibi, M., et al., Evaluation of Availability, Prices, and Affordability of Selected Essential Medicines in Balochistan, Pakistan.
International Journal of Public Health, 2022. 67: p. 1604375.
71. Najmi, M., et al., Prescribing practices: an overview of three teaching hospitals in Pakistan. JPMA. The Journal of the Pakistan
Medical Association, 1998. 48(3): p. 73-77.
72. Riaz, H., et al., Assessment of antibiotic prescribing behavior of consultants of different localities of Pakistan. Afr J Pharm
Pharmacol, 2011. 5(5): p. 596-601.
73. Malik, M., et al. Mind lines against guidelines in treatment of malaria. A Comparative Cross Sectional Study from Pakistan. in
Anales de la Real Academia Nacional de Farmacia. 2012. REAL ACAD NACIONAL FARMACIA FARMACIA, 9 Y 11, MADRID, 00000,
SPAIN.
74. Khan, A.A., J.I. Marvi, and M. Nadeem, PRESCRIBING PRACTICES OF GENERAL PRACTITONARS OF PUBLIC HOSPITALS OF
PAKISTAN. 2013.
75. Akhtar, M.S., et al., Assesment of prescribing practices of private GP’S in Islamabad. Int J Curr Pharm Res, 2013. 5(1): p. 49-53.
76. Ullah, H., et al., Assessment of Prescribing Practices of Prescribers in Abbottabad, Pakistan, using WHO Guidelines. Lat Am J
Pharm, 2013. 32(7): p. 1098-1101.
77. Shahbaz, R., et al., Evaluation of Prescriptions Quality and Estimation of Antibiotics Prescribing According to Different Classes
In Community Pharmacies of Lahore.
78. Babar, H., et al., Adherence to prescription format and compliance with who core prescribing indicators. Journal of
Pharmaceutical Sciences and Research, 2014. 6(4): p. 195.
79. Siddiqui, T., et al., Prescription Writing Trends of General Practitioners in Karachi, Pakistan. Int J Sci Eng Res, 2015. 6(2).
80. Aslam, A., et al., Evaluation of rational drug use at teaching hospitals in Punjab, Pakistan. Journal of Pharmacy Practice and
Community Medicine, 2016. 2(2).
81. Ashar, S.M., et al., Assessment of Drug Use Pattern Using WHO Prescribing Indicators in the Medication Therapy of Indoor
Diabetic Patients. International Journal of Basic Medical Sciences and Pharmacy (IJBMSP), 2016. 6(1).
82. Riaz, H., et al., Evaluation of drug use indicators for non-communicable diseases in Pakistan. interactions, 2016. 18: p. 19.
83. Atif, M., et al., Assessment of WHO/INRUD core drug use indicators in two tertiary care hospitals of Bahawalpur, Punjab,
Pakistan. Journal of pharmaceutical policy and practice, 2016. 9: p. 1-8.
84. Atif, M., et al., Assessment of core drug use indicators using WHO/INRUD methodology at primary healthcare centers in
Bahawalpur, Pakistan. BMC health services research, 2016. 16(1): p. 1-9.
85. Atif, M., et al., Investigation of antimicrobial use at a tertiary care hospital in Southern Punjab, Pakistan using WHO methodology.
Antimicrobial Resistance & Infection Control, 2017. 6: p. 1-12.
86. Hussain, H., et al., Prescription Pattern and Prescription Errors: A Retrospective Study of In-patient’s Record at a Tertiary Care
Hospital Peshawar, Pakistan. International Journal of Basic Medical Sciences and Pharmacy (IJBMSP), 2017. 7(1).
87. Hussain, H., et al., ASSESSMENT OF PRESCRIPTION PATTERN AND PRESCRIPTION ERRORS USING THE WORLD HEALTH
ORGANIZATION DRUG USE INDICATORS IN LADY READING HOSPITAL PESHAWAR, PAKISTAN: A RETROSPECTIVE STUDY. Khyber
Medical University Journal, 2017. 9(4).
88. Mahmood, S., et al., Trends in the prescribing of antipsychotic medicines in Pakistan: implications for the future. Current
medical research and opinion, 2019. 35(1): p. 51-61.
89. Atif, M., et al., Evaluation of prescription errors and prescribing indicators in the private practices in Bahawalpur, Pakistan.
Journal of the Chinese Medical Association, 2018. 81(5): p. 444-449.
90. Khan, Z., et al., Assessment of medication usage in geriatric wards in a teaching hospital. Indian Journal of Pharmacy Practice,
2019. 12(4).
91. Khan, Z., et al., Utilization pattern of antibiotics and patient care indicators in the teaching hospitals, Islamabad, Pakistan. SN
Comprehensive Clinical Medicine, 2019. 1: p. 812-816.
92. Farooq, M.A., et al., WHO indicators and its compliance by general practitioners of Lahore, Pakistan. Iranian Journal of
Pharmaceutical Sciences, 2019. 15(1): p. 67-74.
93. Khalid, T., et al., Analysis of Essential Medicines Used for Emergency Care in Pakistan. Pakistan Journal of Surgery and Medicine.
1(1): p. 75-77. 94. Hafeez, H., et al., Evaluation of rational drug use among pediatrics by using WHO core drug use indicators in selected hospitals
of Pakistan. International Journal of Pharmaceutical Research, 2020(1).
95. Muhammad, K., et al., Pharmacotherapy Assessment by WHO Core Prescribing Pattern in a Teaching Hospital in the Capital
City, Islamabad, Pakistan. Lat. Am. J. Pharm, 2021. 40(5): p. 1060-6.
96. Kamran, S., et al., Prescription analysis and cost of antidepressant drugs in major depressive disorder outpatients at the
tertiary care hospital of Pakistan: a prospective approach. Expert review of pharmacoeconomics & outcomes research, 2022.
22(5): p. 845-851.
97. Omer, S., B.T. Khan, and O. Jalil, EVALUATION OF DRUG--PRESCRIBING PATTERNS AT OUTPATIENT CLINICS OF PUBLIC HEALTH
FACILITIES IN MIRPUR AZAD KASHMIR. Pakistan Armed Forces Medical Journal, 2021. 71(4).
98. Abbas, M., et al., Prescribing practices at a secondary healthcare setting of Islamabad, Pakistan: a descriptive cross-sectional
study. Journal of Pharmaceutical Health Services Research, 2021. 12(2): p. 152-158.
99. Rahim, N., et al., Patterns of drug prescribing and prescribing errors at in-patient pediatric departments of government
hospitals, Karachi, Pakistan. Southeast Asian Journal of Tropical Medicine and Public Health, 2021. 52(2): p. 342-353.
100. Muhammad, W., et al., Drug Prescribing Pattern Observed during Pharmacotherapy of Antibiotics in Medical Wards at Saidu
Group of Teaching Hospital, Khyber Pakhtunkhwa, Pakistan. Authorea Preprints, 2022.
101. Ur Rahman, J., et al., Assessment of prescribing patterns and medication errors related to prescriptions in hospitalized diabetes
mellitus type-2 patients in Khyber Pakhtunkhwa, Pakistan. Journal of Pharmaceutical Health Services Research, 2023. 14(1):
p. 49-54.
102. Atif, M. Why uptake of generic prescribing policy is not feasible in Pakistan: Highlighting need for pro-generic medicine
policies. Pakistan Observer 2020 [cited 2023 1st November]; Available from: https://pakobserver.net/why-uptake-of-genericprescribing-
policy-is-not-feasible-in-pakistan-highlighting-need-for-pro-generic-medicine-policies/.
103. PAKISTAN, D.R.A.O. The Drugs Act, 197. [cited 2024 19 Jan]; Available from: https://www.dra.gov.pk/wp-content/
uploads/2022/10/Drugs-Act-1976.pdf.
104. Rasheed, H., et al., Regulatory framework in Pakistan: situation analysis of medicine quality and future recommendations.
Journal of Pharmaceutical Policy and Practice, 2019. 12(1): p. 23.
105. Gwaza, L., et al., Adjusted indirect treatment comparison of the bioavailability of WHO-prequalified first-line generic
antituberculosis medicines. Clin Pharmacol Ther, 2014. 96(5): p. 580-8.
106. Punjab, G.o. Punjab Drug Rules, 2007. [cited 2024 19 Jan]; Available from: https://punjabcode.punjab.gov.pk/en/show_
article/Bz9dbgI1U2E-.
107. Mahdi, L.A., D.J. Kadhim, and A.A. Al-Jumaili, Knowledge, perception and attitude regarding generic medicines among Iraqi
physicians. INNOVATIONS in pharmacy, 2020. 11(1).
108. Mohammed, A.S., N.A. Woldekidan, and F.A. Mohammed, Knowledge, attitude, and practice of pharmacy professionals on
generic medicines in Eastern Ethiopia: A cross-sectional study. PLoS One, 2020. 15(7): p. e0235205.
109. Qu, J., et al., Knowledge, perceptions and practices of pharmacists regarding generic substitution in China: a cross-sectional
study. BMJ open, 2021. 11(10): p. e051277.
110. R, M.C.C., K. L., and V.R. M., Generic drugs: a study on awareness among medical students and interns. International Journal
of Basic & Clinical Pharmacology, 2020. 9(12).
111. Souliotis, K., et al., Exploring knowledge and perceptions on generic drugs of final year pharmacy school students in Greece.
Expert Review of Pharmacoeconomics & Outcomes Research, 2019. 19(5): p. 569-574.
112. Yang, H., et al., Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China. Health Policy
and Planning, 2009. 25(3): p. 219-229.
113. Sun, X., et al., Availability, prices and affordability of essential medicines for children: a cross-sectional survey in Jiangsu
Province, China. BMJ Open, 2018. 8(10): p. e023646.
114. Babar, Z.U.D., et al., Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in
Malaysia. PLoS medicine, 2007. 4(3): p. e82.
115. Kokabisaghi, F., et al., Availability and affordability of cardiovascular medicines in a major city of Afghanistan in 2020. DARU
Journal of Pharmaceutical Sciences, 2022. 30(2): p. 343-350.
116. Alefan, Q., R. Amairi, and S. Tawalbeh, Availability, prices and affordability of selected essential medicines in Jordan: a national
survey. BMC Health Services Research, 2018. 18(1): p. 787.
117. Aravamuthan, A., et al., Assessment of current prescribing practices using World Health Organization core drug use and
complementary indicators in selected rural community pharmacies in Southern India. Journal of Pharmaceutical Policy and
Practice, 2016. 10(1): p. 1.
118. Kilipamwambu, A., et al., WHO/INRUD core prescribing indicators and antibiotic utilization patterns among primary health
care facilities in Ilala district, Tanzania. JAC-Antimicrobial Resistance, 2021. 3(2): p. dlab049.
sustainabledevelopment/sustainable-development-goals/.
2. Organization, W.H. Access to medicines: making market forces serve the poor. 2017 [cited 2023 August 21 ];
Available from: https://cdn.who.int/media/docs/default-source/essential-medicines/fair-price/chapter-medicines.
pdf?sfvrsn=adcffc8f_4&download=true#:~:text=The%20world%20is%20neither.,in%20modern%20science%20and%20
medicine.&text=When%20prices%20are%20so%20low,profits%2C%20companies%20leave%20the%20market.
3. Protection, N.f.C. Prices, availability and affordability of medicines in Pakistan. [cited 2023 June 30]; Available from: https://
haiweb.org/wp-content/uploads/2015/07/Pakistan-Report-Pricing-Surveys.pdf.
4. Harrison, M.A., et al., Access to cardiovascular medicines in low-and middle-income countries: a mini review. Global Health
Research and Policy, 2023. 8(1): p. 17.
5. Godman, B., et al., Generic drugs–essential for the sustainability of healthcare systems with numerous strategies to enhance
their use. Pharmaceutical Sciences And Biomedical Analysis Journal, 2021. 4(1): p. 126.
6. Godman, B., et al., Evidence-based public policy making for medicines across countries: findings and implications for the
future. Journal of comparative effectiveness research, 2021. 10(12): p. 1019-1052. 7. Cameron, A., et al., Switching from originator brand medicines to generic equivalents in selected developing countries: how
much could be saved? Value in health, 2012. 15(5): p. 664-673.
8. Woerkom, M.v., et al., Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The
Netherlands: influence and future implications. Journal of comparative effectiveness research, 2012. 1(6): p. 527-538.
9. Godman, B., et al., Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization:
changes seen and global implications. Expert review of pharmacoeconomics & outcomes research, 2010. 10(6): p. 707-722.
10. Leporowski, A., et al., Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national
health service: influence and implications. Expert review of pharmacoeconomics & outcomes research, 2018. 18(6): p. 655-
666.
11. Zanichelli, V., et al., The WHO AWaRe (Access, Watch, Reserve) antibiotic book and prevention of antimicrobial resistance.
Bulletin of the World Health Organization, 2023. 101(4): p. 290.
12. Sharland, M., et al., Encouraging AWaRe-ness and discouraging inappropriate antibiotic use—the new 2019 Essential Medicines
List becomes a global antibiotic stewardship tool. The Lancet Infectious Diseases, 2019. 19(12): p. 1278-1280.
13. McCabe, H., et al., Prescribing trends of inhaler treatments for asthma and chronic obstructive pulmonary disease within
a resource-constrained environment in the Scottish national health service: findings and implications. Expert review of
respiratory medicine, 2019. 13(7): p. 679-689.
14. Abdulsalim, S., et al., Structured pharmacist-led intervention programme to improve medication adherence in COPD patients:
a randomized controlled study. Research in Social and Administrative Pharmacy, 2018. 14(10): p. 909-914.
15. Dylst, P., et al., Generic medicines: solutions for a sustainable drug market? Applied health economics and health policy, 2013.
11: p. 437-443.
16. Organization, W.H. Glossary of Globalization, Trade and Health Terms. 2012 [cited 2023 July 14]; Available from: www.who.
int/trade/glossary/ story034/en/index.html.
17. Suleman, F., et al., New business models for research and development with affordability requirements are needed to achieve
fair pricing of medicines. bmj, 2020. 368.
18. Godman, B., et al., Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of
healthcare systems and the implications. Expert review of pharmacoeconomics & outcomes research, 2021. 21(4): p. 527-540.
19. Hollis, A., Orphan drug pricing and costs: a case study of Kalydeco and Orkambi. Healthcare policy, 2019. 15(1): p. 70.
20. Workman, P., et al., How much longer will we put up with $100,000 cancer drugs? Cell, 2017. 168(4): p. 579-583.
21. Manzoli, L., et al., Generic versus brand-name drugs used in cardiovascular diseases. European journal of epidemiology, 2016.
31: p. 351-368.
22. Kesselheim, A.S., et al., Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic
review and meta-analysis. Jama, 2008. 300(21): p. 2514-2526.
23. Corrao, G., et al., Are generic and brand-name statins clinically equivalent? Evidence from a real data-base. European journal
of internal medicine, 2014. 25(8): p. 745-750.
24. Lessing, C., T. Ashton, and P. Davis, The impact on health outcomes and healthcare utilisation of switching to generic medicines
consequent to reference pricing: the case of lamotrigine in New Zealand. Applied health economics and health policy, 2014.
12: p. 537-546.
25. Jamshed, S.Q., M.A.A. Hassali, and M.I.M.J.J.T.J.o.t.P.M.A. Ibrahim, Knowledge attitude and perception of dispensing doctors
regarding generic medicines in Karachi, Pakistan: a qualitative study. 2011. 61(1): p. 80-83.
26. Das, N., et al., Prescribing practices of consultants at Karachi, Pakistan. 2001. 51(2): p. 74-77.
27. Aijaz, T. Generic Drugs: A Better Alternative for Low Income Countries. 2015 [cited 2023 July 28]; Available from: http://blogs.
jpmsonline.com/2015/09/19/generic-drugs-a-better-alternative-for-low-income-countries/.
28. MacBride-Stewart, S., et al., Initiatives and reforms across Scotland in recent years to improve prescribing; findings and global
implications of drug prescriptions. International Journal of Clinical and Experimental Medicine, 2021. 14(12): p. 2563-2586.
29. Garuoliene, K., et al., European countries with small populations can obtain low prices for drugs: Lithuania as a case history.
Expert review of pharmacoeconomics & outcomes research, 2011. 11(3): p. 343-349.
30. Markovic-Pekovic, V., et al., Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future
directions. Expert review of pharmacoeconomics & outcomes research, 2012. 12(5): p. 661-671.
31. Garuolienė, K., et al., Differences in utilization rates between commercial and administrative databases: implications for future
health-economic and cross-national studies. Expert review of pharmacoeconomics & outcomes research, 2016. 16(2): p. 149-
152.
32. Bayram, D., et al., Generic drug prescribing in primary care: A nationwide analysis. International Journal of Clinical Practice,
2021. 75(8): p. e14284.
33. Wong, J.Q., et al., The prevalence of Philippine prescribing, dispensing, and use behavior in relation to generic drugs and their
risk factors. 2014, PIDS Discussion Paper Series.
34. Lavtepatil, S. and S. Ghosh, Improving access to medicines by popularising generics: a study of ‘India’s People’s Medicine’scheme
in two districts of Maharashtra. BMC Health Services Research, 2022. 22(1): p. 643.
35. Pharmacopeia, U.S. Timeline: Generic medicines in the US. 2018 [cited 2023 July 31]; Available from: https://www.usp.org/our-impact/generics/timeline-of-generics-in-us.
36. Zaheer-Ud-Din Babar, S.Q.J., Ashar Muhammad Malik, Hans Löfgren, The New Political Economy of Pharmaceuticals. The
Pharmaceutical Industry, Intellectual Property Rights and Access to Medicines in Pakistan. 2013: Springer.
37. Merchant, H.A., et al., A leap towards enforcing medicines prescribing by generic names in low-and middle-income countries
(LMICs): pitfalls, limitations, and recommendations for local drug regulatory agencies. 2022. 15(1): p. 1-7.
38. Babar, A., et al., Assessment of active pharmaceutical ingredients in drug registration procedures in Pakistan: implications for
the future. Generics and Biosimilars Initiative Journal, 2016. 5(4): p. 156-163.
39. Arnet, I., et al., Pharmaceutical quality of eight generics of ceftriaxone preparation for injection in Eastern Asia. Journal of
chemotherapy, 2015. 27(6): p. 337-342.
40. Redfern, J., et al., Equivalence in active pharmaceutical ingredient of generic antihypertensive medicines available in Nigeria
(EQUIMEDS): a case for further surveillance. Global heart, 2019. 14(3): p. 327-333.
41. Fadare, J.O., et al., The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians. Expert
review of pharmacoeconomics & outcomes research, 2016. 16(5): p. 639-650.
42. Bank, T.W. Data for Lower middle income, Pakistan 2023 [cited 2023 Aug 2]; Available from: https://data.worldbank.
org/?locations=XN-PK.
43. Saeed, A., et al., Access to essential cardiovascular medicines in Pakistan: a national survey on the availability, price, and
affordability, using WHO/HAI methodology. 2021. 11: p. 595008.
44. Saeed, A., et al., Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A crosssectional
survey using WHO/HAI methodology. 2019. 14(4): p. e0216122.
45. Saleem, F., et al., Uncontrollable medicine prices in Pakistan. 2016. 388(10060): p. 2602.
46. Jamshed, S.Q., et al., Perception and attitude of general practitioners regarding generic medicines in Karachi, Pakistan: a
questionnaire based study. 2012. 5(1): p. 22.
47. Godman, B., et al., Evidence-based public policy making for medicines across countries: findings and implications for the
future. J Comp Eff Res, 2021. 10(12): p. 1019-1052.
48. Saeed, A., et al., Impact of National Drug Pricing Policy 2018 on access to medicines in Lahore division, Pakistan: a pre-post
survey study using WHO/HAI methodology. BMJ open, 2020. 10(10): p. e034720.
49. Zaidi, S., et al., Access to essential medicines in Pakistan: policy and health systems research concerns. PloS one, 2013. 8(5):
p. e63515.
50. McGinn, D., et al., Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and
implications. Expert review of pharmacoeconomics & outcomes research, 2010. 10(1): p. 73-85.
51. Zaidi, S., et al., Access to essential medicines in Pakistan: policy and health systems research concerns. 2013. 8(5): p. e63515.
52. INITIATIVE, G.A.B. Generics in Pakistan. 2012 [cited 2023 Aug 2]; Available from: https://www.gabionline.net/generics/
research/Generics-in-Pakistan.
53. Pakistan, D.R.A.o. Amendments in the Drug Pricing Policy-2018. [cited 2023 December 13]; Available from: https://www.dra.
gov.pk/about_us/legislation/sros/sro-678i-2023-amendments-in-the-drug-pricing-policy-2018/.
54. Merchant, H.A., Z.-U.-D. Babar, and I.M. Hussain, A leap towards enforcing medicines prescribing by generic names in low-and
middle-income countries (LMICs): pitfalls, limitations, and recommendations for local drug regulatory agencies. Journal of
Pharmaceutical Policy and Practice, 2022. 15(1): p. 1-7.
55. Pakistan, D.R.A.o. Applications for Registration of Multiple Strength and Volume Drugs (Pharmaceutical) on Form-5F. [cited
2023 December 16]; Available from: https://www.dra.gov.pk/news_updates/regulatory_updates/drugs/notificationregarding-
data-requirements-of-form-5-f-for-pharmaceutical-drug-products-having-multiple-strengths-fill-volumes/.
56. Hasan, S.K.J.J.o.t.D.U.o.H.S., Prospects of drug bioequivalence studies in Pakistan. 2012. 6(2): p. 39-41.
57. News, T. Generic Medicines Flooding Market Sans Tests, Research. 2012 [cited 2023 Aug 6]; Available from: https://www.
thenews.com.pk/archive/print/343372-generic-medicines-flooding-market-sans--tests-research .
58. Khan, N., et al., Perceptions and attitudes of medical sales representatives (MSRs) and prescribers regarding pharmaceutical
sales promotion and prescribing practices in Pakistan. 2016. 8(3): p. 244-250.
59. Alam, M., et al., Tackling antimicrobial resistance in primary care facilities across Pakistan: Current challenges and implications
for the future. Journal of Infection and Public Health, 2023.
60. Abdullah, S., Z. Saleem, and B. Godman, Coping with increasing medicine costs through greater adoption of generic prescribing
and dispensing in Pakistan as an exemplar country. 2024, Taylor & Francis. p. 167-170.
61. Haddaway, N.R., et al., PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with
interactivity for optimised digital transparency and Open Synthesis. Campbell Systematic Reviews, 2022. 18(2): p. e1230.
62. Jamshed, S., et al., Knowledge, perception and attitude of community pharmacists towards generic medicines in Karachi,
Pakistan: a qualitative insight. Tropical Journal of Pharmaceutical Research, 2010. 9(4).
63. Jamshed, S.Q., et al., Understanding and perceptions of final-year Doctor of Pharmacy students about generic medicines in
Karachi, Pakistan: a quantitative insight. 2015: p. 359-366.
64. Masood, I., A. Saleem, and S.Q.J.J.o.P.H.S.R. Jamshed, Why do physicians prefer brand medicines over generic medicines in
Pakistan? A quantitative approach. 2016. 7(4): p. 247-251. 65. Asif, U., et al., Exploring the knowledge and attitude of medical and pharmacy students about generic medicine in Lahore,
Pakistan. Journal of Generic Medicines, 2018. 14(1): p. 22-28.
66. Tauqeer Hussain MALLHI, Y.H.K., Shahid SHAH, Ghulam ABBAS, Usman Rashid CHAND, Knowledge, Attitude and Practice of
Community Pharmacists Regarding Generic Medicines: A National Cross-Sectional Survey. Latin American Journal of Pharmacy,
2022. 41(10): p. 1962-70.
67. Sarwar, M.R., S. Iftikhar, and A. Saqib, Availability of anticancer medicines in public and private sectors, and their affordability
by low, middle and high-income class patients in Pakistan. BMC cancer, 2018. 18(1): p. 1-11.
68. Saqib, A., S. Iftikhar, and M.R. Sarwar, Availability and affordability of biologic versus non-biologic anticancer medicines: a
cross-sectional study in Punjab, Pakistan. BMJ open, 2018. 8(6): p. e019015.
69. Saleem, Z., et al., WHO key access antibiotics prices, availability and affordability in private sector pharmacies in Pakistan. Cost
Effectiveness and Resource Allocation, 2021. 19(1): p. 1-10.
70. Bibi, M., et al., Evaluation of Availability, Prices, and Affordability of Selected Essential Medicines in Balochistan, Pakistan.
International Journal of Public Health, 2022. 67: p. 1604375.
71. Najmi, M., et al., Prescribing practices: an overview of three teaching hospitals in Pakistan. JPMA. The Journal of the Pakistan
Medical Association, 1998. 48(3): p. 73-77.
72. Riaz, H., et al., Assessment of antibiotic prescribing behavior of consultants of different localities of Pakistan. Afr J Pharm
Pharmacol, 2011. 5(5): p. 596-601.
73. Malik, M., et al. Mind lines against guidelines in treatment of malaria. A Comparative Cross Sectional Study from Pakistan. in
Anales de la Real Academia Nacional de Farmacia. 2012. REAL ACAD NACIONAL FARMACIA FARMACIA, 9 Y 11, MADRID, 00000,
SPAIN.
74. Khan, A.A., J.I. Marvi, and M. Nadeem, PRESCRIBING PRACTICES OF GENERAL PRACTITONARS OF PUBLIC HOSPITALS OF
PAKISTAN. 2013.
75. Akhtar, M.S., et al., Assesment of prescribing practices of private GP’S in Islamabad. Int J Curr Pharm Res, 2013. 5(1): p. 49-53.
76. Ullah, H., et al., Assessment of Prescribing Practices of Prescribers in Abbottabad, Pakistan, using WHO Guidelines. Lat Am J
Pharm, 2013. 32(7): p. 1098-1101.
77. Shahbaz, R., et al., Evaluation of Prescriptions Quality and Estimation of Antibiotics Prescribing According to Different Classes
In Community Pharmacies of Lahore.
78. Babar, H., et al., Adherence to prescription format and compliance with who core prescribing indicators. Journal of
Pharmaceutical Sciences and Research, 2014. 6(4): p. 195.
79. Siddiqui, T., et al., Prescription Writing Trends of General Practitioners in Karachi, Pakistan. Int J Sci Eng Res, 2015. 6(2).
80. Aslam, A., et al., Evaluation of rational drug use at teaching hospitals in Punjab, Pakistan. Journal of Pharmacy Practice and
Community Medicine, 2016. 2(2).
81. Ashar, S.M., et al., Assessment of Drug Use Pattern Using WHO Prescribing Indicators in the Medication Therapy of Indoor
Diabetic Patients. International Journal of Basic Medical Sciences and Pharmacy (IJBMSP), 2016. 6(1).
82. Riaz, H., et al., Evaluation of drug use indicators for non-communicable diseases in Pakistan. interactions, 2016. 18: p. 19.
83. Atif, M., et al., Assessment of WHO/INRUD core drug use indicators in two tertiary care hospitals of Bahawalpur, Punjab,
Pakistan. Journal of pharmaceutical policy and practice, 2016. 9: p. 1-8.
84. Atif, M., et al., Assessment of core drug use indicators using WHO/INRUD methodology at primary healthcare centers in
Bahawalpur, Pakistan. BMC health services research, 2016. 16(1): p. 1-9.
85. Atif, M., et al., Investigation of antimicrobial use at a tertiary care hospital in Southern Punjab, Pakistan using WHO methodology.
Antimicrobial Resistance & Infection Control, 2017. 6: p. 1-12.
86. Hussain, H., et al., Prescription Pattern and Prescription Errors: A Retrospective Study of In-patient’s Record at a Tertiary Care
Hospital Peshawar, Pakistan. International Journal of Basic Medical Sciences and Pharmacy (IJBMSP), 2017. 7(1).
87. Hussain, H., et al., ASSESSMENT OF PRESCRIPTION PATTERN AND PRESCRIPTION ERRORS USING THE WORLD HEALTH
ORGANIZATION DRUG USE INDICATORS IN LADY READING HOSPITAL PESHAWAR, PAKISTAN: A RETROSPECTIVE STUDY. Khyber
Medical University Journal, 2017. 9(4).
88. Mahmood, S., et al., Trends in the prescribing of antipsychotic medicines in Pakistan: implications for the future. Current
medical research and opinion, 2019. 35(1): p. 51-61.
89. Atif, M., et al., Evaluation of prescription errors and prescribing indicators in the private practices in Bahawalpur, Pakistan.
Journal of the Chinese Medical Association, 2018. 81(5): p. 444-449.
90. Khan, Z., et al., Assessment of medication usage in geriatric wards in a teaching hospital. Indian Journal of Pharmacy Practice,
2019. 12(4).
91. Khan, Z., et al., Utilization pattern of antibiotics and patient care indicators in the teaching hospitals, Islamabad, Pakistan. SN
Comprehensive Clinical Medicine, 2019. 1: p. 812-816.
92. Farooq, M.A., et al., WHO indicators and its compliance by general practitioners of Lahore, Pakistan. Iranian Journal of
Pharmaceutical Sciences, 2019. 15(1): p. 67-74.
93. Khalid, T., et al., Analysis of Essential Medicines Used for Emergency Care in Pakistan. Pakistan Journal of Surgery and Medicine.
1(1): p. 75-77. 94. Hafeez, H., et al., Evaluation of rational drug use among pediatrics by using WHO core drug use indicators in selected hospitals
of Pakistan. International Journal of Pharmaceutical Research, 2020(1).
95. Muhammad, K., et al., Pharmacotherapy Assessment by WHO Core Prescribing Pattern in a Teaching Hospital in the Capital
City, Islamabad, Pakistan. Lat. Am. J. Pharm, 2021. 40(5): p. 1060-6.
96. Kamran, S., et al., Prescription analysis and cost of antidepressant drugs in major depressive disorder outpatients at the
tertiary care hospital of Pakistan: a prospective approach. Expert review of pharmacoeconomics & outcomes research, 2022.
22(5): p. 845-851.
97. Omer, S., B.T. Khan, and O. Jalil, EVALUATION OF DRUG--PRESCRIBING PATTERNS AT OUTPATIENT CLINICS OF PUBLIC HEALTH
FACILITIES IN MIRPUR AZAD KASHMIR. Pakistan Armed Forces Medical Journal, 2021. 71(4).
98. Abbas, M., et al., Prescribing practices at a secondary healthcare setting of Islamabad, Pakistan: a descriptive cross-sectional
study. Journal of Pharmaceutical Health Services Research, 2021. 12(2): p. 152-158.
99. Rahim, N., et al., Patterns of drug prescribing and prescribing errors at in-patient pediatric departments of government
hospitals, Karachi, Pakistan. Southeast Asian Journal of Tropical Medicine and Public Health, 2021. 52(2): p. 342-353.
100. Muhammad, W., et al., Drug Prescribing Pattern Observed during Pharmacotherapy of Antibiotics in Medical Wards at Saidu
Group of Teaching Hospital, Khyber Pakhtunkhwa, Pakistan. Authorea Preprints, 2022.
101. Ur Rahman, J., et al., Assessment of prescribing patterns and medication errors related to prescriptions in hospitalized diabetes
mellitus type-2 patients in Khyber Pakhtunkhwa, Pakistan. Journal of Pharmaceutical Health Services Research, 2023. 14(1):
p. 49-54.
102. Atif, M. Why uptake of generic prescribing policy is not feasible in Pakistan: Highlighting need for pro-generic medicine
policies. Pakistan Observer 2020 [cited 2023 1st November]; Available from: https://pakobserver.net/why-uptake-of-genericprescribing-
policy-is-not-feasible-in-pakistan-highlighting-need-for-pro-generic-medicine-policies/.
103. PAKISTAN, D.R.A.O. The Drugs Act, 197. [cited 2024 19 Jan]; Available from: https://www.dra.gov.pk/wp-content/
uploads/2022/10/Drugs-Act-1976.pdf.
104. Rasheed, H., et al., Regulatory framework in Pakistan: situation analysis of medicine quality and future recommendations.
Journal of Pharmaceutical Policy and Practice, 2019. 12(1): p. 23.
105. Gwaza, L., et al., Adjusted indirect treatment comparison of the bioavailability of WHO-prequalified first-line generic
antituberculosis medicines. Clin Pharmacol Ther, 2014. 96(5): p. 580-8.
106. Punjab, G.o. Punjab Drug Rules, 2007. [cited 2024 19 Jan]; Available from: https://punjabcode.punjab.gov.pk/en/show_
article/Bz9dbgI1U2E-.
107. Mahdi, L.A., D.J. Kadhim, and A.A. Al-Jumaili, Knowledge, perception and attitude regarding generic medicines among Iraqi
physicians. INNOVATIONS in pharmacy, 2020. 11(1).
108. Mohammed, A.S., N.A. Woldekidan, and F.A. Mohammed, Knowledge, attitude, and practice of pharmacy professionals on
generic medicines in Eastern Ethiopia: A cross-sectional study. PLoS One, 2020. 15(7): p. e0235205.
109. Qu, J., et al., Knowledge, perceptions and practices of pharmacists regarding generic substitution in China: a cross-sectional
study. BMJ open, 2021. 11(10): p. e051277.
110. R, M.C.C., K. L., and V.R. M., Generic drugs: a study on awareness among medical students and interns. International Journal
of Basic & Clinical Pharmacology, 2020. 9(12).
111. Souliotis, K., et al., Exploring knowledge and perceptions on generic drugs of final year pharmacy school students in Greece.
Expert Review of Pharmacoeconomics & Outcomes Research, 2019. 19(5): p. 569-574.
112. Yang, H., et al., Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China. Health Policy
and Planning, 2009. 25(3): p. 219-229.
113. Sun, X., et al., Availability, prices and affordability of essential medicines for children: a cross-sectional survey in Jiangsu
Province, China. BMJ Open, 2018. 8(10): p. e023646.
114. Babar, Z.U.D., et al., Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in
Malaysia. PLoS medicine, 2007. 4(3): p. e82.
115. Kokabisaghi, F., et al., Availability and affordability of cardiovascular medicines in a major city of Afghanistan in 2020. DARU
Journal of Pharmaceutical Sciences, 2022. 30(2): p. 343-350.
116. Alefan, Q., R. Amairi, and S. Tawalbeh, Availability, prices and affordability of selected essential medicines in Jordan: a national
survey. BMC Health Services Research, 2018. 18(1): p. 787.
117. Aravamuthan, A., et al., Assessment of current prescribing practices using World Health Organization core drug use and
complementary indicators in selected rural community pharmacies in Southern India. Journal of Pharmaceutical Policy and
Practice, 2016. 10(1): p. 1.
118. Kilipamwambu, A., et al., WHO/INRUD core prescribing indicators and antibiotic utilization patterns among primary health
care facilities in Ilala district, Tanzania. JAC-Antimicrobial Resistance, 2021. 3(2): p. dlab049.
Article Sidebar
Published
Oct 8, 2025
Article Details
How to Cite
1.
Barriers to Implement Generic Medicine Prescribing and Dispensing Policies in Pakistan: Current Challenges and Future Implication. Pharm Pract (Granada) [Internet]. 2025 Oct. 8 [cited 2025 Oct. 22];23(3):1-16. Available from: https://pharmacypractice.org/index.php/pp/article/view/3195
Section
Review
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
1.
Barriers to Implement Generic Medicine Prescribing and Dispensing Policies in Pakistan: Current Challenges and Future Implication. Pharm Pract (Granada) [Internet]. 2025 Oct. 8 [cited 2025 Oct. 22];23(3):1-16. Available from: https://pharmacypractice.org/index.php/pp/article/view/3195